Compare Amylx Pharmaceuticals Inc (AMLX) vs Enovix Corporation (ENVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Enovix Corporation — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Enovix Corporation trades at $4.86 (market cap $1.01B). The key difference: Amylx Pharmaceuticals Inc is far larger — about 2.5× Enovix Corporation's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals.
| AMLX | ENVX | |
|---|---|---|
Market Cap | $2.53B | $1.01B |
Sector | Health | Technology |
52-Week High | $24.19 | $13.19 |
52-Week Low | $7.82 | $3.68 |
Enterprise Value | $2.28B | $1.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
ENVX trades at $4.70, up 10.33% today, with a bullish technical signal despite negative profitability. Recent earnings beats and a $12.38 consensus price target suggest upside potential. The company is ramping production of advanced silicon-anode batteries, with key developments including a new COO appointment and upcoming Q2 2026 results on August 12, 2026.
Outlook remains speculative with high revenue growth potential but persistent losses; risks include cash burn and competitive pressures. Analyst sentiment is positive (75% buy ratings), but investors should weigh the long-term growth story against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →
